Drug Trial Radar · NCT03760146
Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
Last checked: Nov 19, 2026Latest source record: Dec 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,902
Actual
Start
Dec 12, 2018
Primary completion
Dec 16, 2019
Study completion Dec 16, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
Conditions
- Pneumococcal Disease
Interventions
20vPnCBiological
20vPnC
13vPnCBiological
Pneumococcal conjugate vaccine
PPSV23Biological
Pneumococcal polysaccharide vaccine
SalineOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Local Reactions Within 10 Days After Vaccination in All CohortsTime frame: Within 10 days after 20vPnC or 13vPnC
- Percentage of Participants With Systemic Events Within 7 Days After Vaccination in All CohortsTime frame: Within 7 days after 20vPnC or 13vPnC
- Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination in All CohortsTime frame: Within 1 month after 20vPnC or 13vPnC
- Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination in All CohortsTime frame: Within 6 months after 20vPnC or 13vPnC
- Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination in All CohortsTime frame: Within 6 months after 20vPnC or 13vPnC
- Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC) in Cohort 1: Evaluable 13-Matched Immunogenicity PopulationTime frame: 1 month after Vaccination 1
- Pneumococcal OPA GMTs for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23) in Cohort 1: Evaluable 7-Additional Immunogenicity Population (E7-AIP)Time frame: 1 month after Vaccination 1 in "Cohort 1: 20vPnC/Saline"; 1 month after Vaccination 2 in "Cohort 1: 13vPnC/PPSV23"
Locations
68 sites in 2 countries. Site status is shown where the registry gives one.
Accel Research Sites
Birmingham, Alabama
Coastal Clinical Research, Inc.
Mobile, Alabama
East Valley Gastroenterology and Hepatology Associates
Chandler, Arizona
The Pain Center of Arizona
Peoria, Arizona
MedPharmics, LLC
Phoenix, Arizona
HOPE Research Institute
Phoenix, Arizona
The Pain Center of Arizona
Phoenix, Arizona
Anaheim Clinical Trials, LLC
Anaheim, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Clinical Research Consulting, LLC
Milford, Connecticut
Nature Coast Clinical Research
Crystal River, Florida
Accel Research Sites - Clinical Research Unit
DeLand, Florida
Research Centers of America, LLC
Hollywood, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Suncoast Research Group, LLC
Miami, Florida
Acevedo Clinical Research Associates
Miami, Florida
Qps-Mra, Llc
South Miami, Florida
Atlanta Center for Medical Research
Atlanta, Georgia
Meridian Clinical Research LLC
Savannah, Georgia
Clinical Research Atlanta
Stockbridge, Georgia
East-West Medical Research Institute
Honolulu, Hawaii
Axtell Clinic, P.A.
Newton, Kansas
Heartland Research Associates, LLC
Newton, Kansas
Heartland Research Associates, LLC
Wichita, Kansas
Northwest Family Physicians
Wichita, Kansas
Heartland Research Associates, LLC
Wichita, Kansas
Meridian Clinical Research, LLC
Rockville, Maryland
Sundance Clinical Research
St Louis, Missouri
Meridian Clinical Research, LLC
Norfolk, Nebraska
Meridian Clinical Research LLC
Omaha, Nebraska
ActivMed Practices & Research, Inc.
Portsmouth, New Hampshire
United Medical Associates
Binghamton, New York
Regional Clinical Research, Inc.
Endwell, New York
Rochester Clinical Research, Inc.
Rochester, New York
PharmQuest
Greensboro, North Carolina
M3 Wake Research, Inc.
Raleigh, North Carolina
PMG Research of Wilmington, LLC
Wilmington, North Carolina
Lillestol Research LLC
Fargo, North Dakota
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Sterling Research Group, Ltd.
Cincinnati, Ohio
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.